Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
…, I Tirosh, L Imundo, R Jerath, DJ Kingsbury… - The Lancet, 2021 - thelancet.com
Background Tofacitinib is an oral Janus kinase inhibitor. This trial assessed the efficacy and
safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic …
safety of tofacitinib versus placebo in patients with polyarticular course juvenile idiopathic …
[HTML][HTML] HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum
NS Dangoria, ML DeLay, DJ Kingsbury, JP Mear… - Journal of Biological …, 2002 - ASBMB
The class I protein HLA-B27 confers susceptibility to inflammatory arthritis in humans and
when overexpressed in rodents for reasons that remain unclear. We demonstrated previously …
when overexpressed in rodents for reasons that remain unclear. We demonstrated previously …
Classification, presentation, and initial treatment of Wegener's granulomatosis in childhood
…, AS Zeft, DJ Lovell, DJ Kingsbury… - … : Official Journal of …, 2009 - Wiley Online Library
Objective To compare the criteria for Wegener's granulomatosis (WG) of the American
College of Rheumatology (ACR) with those of the European League Against Rheumatism/…
College of Rheumatology (ACR) with those of the European League Against Rheumatism/…
[HTML][HTML] Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases
…, E Kessler, H Kim, DJ Kingsbury… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Undifferentiated systemic autoinflammatory diseases (USAIDs) present
diagnostic and therapeutic challenges. Chronic interferon (IFN) signaling and cytokine …
diagnostic and therapeutic challenges. Chronic interferon (IFN) signaling and cytokine …
Familial neuromyelitis optica
…, HJ Kim, W Kim, DG Brum, AA Barreira, DJ Kingsbury… - Neurology, 2010 - AAN Enterprises
Background: Detection of aquaporin-4–specific immunoglobulin G (IgG) has expanded the
spectrum of neuromyelitis optica (NMO). Rare reports of familial aggregation have suggested …
spectrum of neuromyelitis optica (NMO). Rare reports of familial aggregation have suggested …
[HTML][HTML] Pediatric Rheumatology Collaborative Study Group–over four decades of pivotal clinical drug research in pediatric rheumatology
HI Brunner, LG Rider, DJ Kingsbury, D Co… - Pediatric …, 2018 - Springer
Importance Specialized research networks are essential to achieve drug approvals for rare
pediatric diseases. Such networks help realize the potential of global legislation enacted …
pediatric diseases. Such networks help realize the potential of global legislation enacted …
Emergent high fatality lung disease in systemic juvenile arthritis
…, R Jerath, K Khawaja, DJ Kingsbury… - Annals of the …, 2019 - ard.bmj.com
Objective To investigate the characteristics and risk factors of a novel parenchymal lung
disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA). Methods In a …
disease (LD), increasingly detected in systemic juvenile idiopathic arthritis (sJIA). Methods In a …
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
…, N Rubio-Pérez, V Keltsev, DJ Kingsbury… - Annals of the …, 2018 - ard.bmj.com
Objective This report aims to determine the safety, pharmacokinetics (PK) and efficacy of
subcutaneous golimumab in active polyarticular-course juvenile idiopathic arthritis (polyJIA). …
subcutaneous golimumab in active polyarticular-course juvenile idiopathic arthritis (polyJIA). …
Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener's): an …
…, K Ede, M Shishov, DJ Kingsbury… - Arthritis & …, 2016 - Wiley Online Library
Objective To uniquely classify children with microscopic polyangiitis (MPA), to describe their
demographic characteristics, presenting clinical features, and initial treatments in …
demographic characteristics, presenting clinical features, and initial treatments in …
[HTML][HTML] Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter …
…, Z Zuber, N Tzaribachev, DJ Kingsbury… - Pediatric …, 2017 - Springer
Background Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease
and a leading cause of childhood disability. The objective of this study was to characterize …
and a leading cause of childhood disability. The objective of this study was to characterize …